Treatment and timing in invasive mould disease
Open Access
- 21 December 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 66 (Supplement) , i37-i43
Abstract
Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early treatment (empirical and pre-emptive therapy) and treatment of documented mould infections in onco-haematology patients are discussed.Keywords
This publication has 45 references indexed in Scilit:
- Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have ZygomycosisClinical Infectious Diseases, 2008
- Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis during Prolonged Neutropenia: A Randomized, Placebo‐Controlled TrialClinical Infectious Diseases, 2008
- Invasive Aspergillosis in the Intensive Care UnitClinical Infectious Diseases, 2007
- Imaging Findings in Acute Invasive Pulmonary Aspergillosis: Clinical Significance of the Halo SignClinical Infectious Diseases, 2007
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Invasive AspergillosisDrugs, 2007
- Invasive Zygomycosis: Update on Pathogenesis, Clinical Manifestations, and ManagementInfectious Disease Clinics of North America, 2006
- Invasive Aspergillosis in Critically Ill Patients without MalignancyAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Detection of Galactomannan Antigenemia by Enzyme Immunoassay for the Diagnosis of Invasive Aspergillosis: Variables That Affect PerformanceThe Journal of Infectious Diseases, 2004